See feature articles below:
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 153% in verifiable potential gains for our members on the last 3 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Report for: KMPH
KemPharm, Inc. (NASDAQ: KMPH) revealed that NASDAQ halted trading of its common stock on Thursday morning. The company was engaged in a clinical-stage specialty pharmaceutical in the discovery and development of proprietary prodrugs.
The move followed after the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the FDA in the United States was slated to meet on Thursday. The meeting was for a public review of the data in the New Drug Application (NDA) for Apadaz (benzhydrocodone hydrochloride and acetaminophen), its investigational abuse-deterrent product candidate for the short-term management of acute pain.
KemPharm pointed out the timelines that was established by the Prescription Drug User Fee Act (PDUFA) and said that the review of the NDA is expected to be complete by June 9, 2016.
The company would host a conference call on Thursday at 6:15 p.m., ET to discuss the FDA’s review of the Apadaz NDA.
On Wednesday, the stock shed 5.55 percent.
Source – Benzinga
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.
Hot small cap stocks
small cap stock picks
FDA approval stocks
Become a day trader
Day trade stocks for a living
PDUFA date set
micro cap stocks
Best stocks 2016
Hottest small cap stocks
Best stock picks
Who to follow for stock picks
Apple news stock picks
Stock picks on apple news